The company agreed to acquire Amicus Therapeutics for $14.50 per share, valuing the deal at approximately $4.8 billion, with the transaction expected to close in Q2 2026. The acquisition adds marketed therapies Galafold and Pombiliti + Opfolda that generated $599 million in net product revenue over the past four quarters, positioning BioMarin as a more diversified rare disease player.
Cyborg Score Rationale
BioMarin demonstrates strong execution with eight commercial therapies, an active clinical pipeline, and major transformational M&A activity. The pending Amicus acquisition significantly expands revenue and therapeutic portfolio, though integration execution risk and debt financing (~$3.7B) warrant monitoring during the next 12 months.
Top Insights
Transformational M&A: $4.8B acquisition of Amicus Therapeutics expected to close Q2 2026, adding $599M in annual revenue
Strong financial position: Company secured $850M notes offering and $2.0B Term Loan B facility to fund acquisition, plus $800M Term Loan A and $600M revolver
Recent earnings guidance: Q4 2025 expected revenue of $834.3M and earnings of $0.80 per share
Patent protection: Amicus acquisition resolves Galafold patent litigation with U.S. exclusivity expected through January 2037